An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis

Maturitas

Volumn 71, Issue 3, 2012, Pages 221-226

  Komm, Barry S ^a   Chines, Arkadi A ^a  

^a PFIZER INC   (United States)

Author keywords

Arzoxifene; Bazedoxifene; Lasofoxifene; Ospemifene; Osteoporosis; SERM

Indexed keywords

ACOLBIFENE; ARZOXIFENE; BAZEDOXIFENE; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LSN 2120310; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ACUTE CHOLECYSTITIS; BONE DENSITY; BONE MASS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANDIDIASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM POLYP; FEMUR NECK; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; LUNG METASTASIS; MENOPAUSAL SYNDROME; MUSCLE CRAMP; MYCOSIS; NONHUMAN; PELVIC ORGAN PROLAPSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYP; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; UTERUS MYOMA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINITIS; VERTEBRA FRACTURE; VULVOVAGINITIS;

BONE DENSITY CONSERVATION AGENTS; BREAST; ENDOMETRIUM; FEMALE; FRACTURES, BONE; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84856961694     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.11.018     Document Type: Review

References (43)

1. E. Dennison, and C. Cooper Epidemiology of osteoporotic fractures Horm Res 54 2000 58 63 (Pubitemid 32037589)
2. J.S. Finkelstein, S.E. Brockwell, and V. Mehta Bone mineral density changes during the menopause transition in a multiethnic cohort of women J Clin Endocrinol Metab 93 2008 861 868 (Pubitemid 351398564)
3. O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 2006 1726 1733 (Pubitemid 44607392)
4. R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, and A. Tosteson Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 2007 465 475 (Pubitemid 46797130)
5. J.A. Kanis, and O. Johnell Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 2005 229 238 (Pubitemid 40379422)
6. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 2003 618 629 (Pubitemid 36210865)
7. H.S. Taylor Designing the ideal selective estrogen receptor modulator - an achievable goal? Menopause 16 2009 609 615
8. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 2008 525 535 (Pubitemid 351501893)
9. S.L. Silverman, C. Christiansen, and H.K. Genant Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 2008 1923 1934
10. J.A. Kanis, O. Johnell, A. Oden, H. Johansson, and E. McCloskey FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 2008 385 397
11. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 2009 1049 1054
12. E. McCloskey, H. Johansson, A. Oden, A. Chines, and J. Kanis Assessment of the effect of bazedoxifene on non-vertebral fracture risk J Bone Miner Res 24 Suppl. 1 2009 Available at: http://www.asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid=6c55b263-692e-4a37-b807-f7a153641564 [accessed 18.10.10]
13. C. Christiansen, C.H. Chesnut III, and J.D. Adachi Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis BMC Musculoskelet Disord 11 2010 130
14. J.V. Pinkerton, D.F. Archer, and W.H. Utian Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 2009 1102 1108
15. D.F. Archer, J.V. Pinkerton, and W.H. Utian Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 2009 1109 1115
16. J.A. Harvey, M.K. Holm, R. Ranganath, P.A. Guse, E.A. Trott, and E. Helzner The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis Menopause 16 2009 1193 1196
17. T.J. de Villiers, A.A. Chines, and S. Palacios Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 22 2011 567 576
18. S.L. Silverman, A.A. Chines, and D.L. Kendler Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos Int 2011 [Epub ahead of print]
19. S. Palacios, S. Silverman, and A.B. Levine Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study Presented at the 13th International Menopause Society World Congress on Menopause June 8-11, 2011, Rome, Italy 2011
20. S. Palacios, T.J. de Villiers, and F. De Cicco-Nardone Reproductive safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study Menopause 18 2011 1344 Abstract S-7
21. J.H. Pickar, and S. Mirkin Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex Menopause Int 16 2010 121 128
22. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 2009 1045 1052
23. R.A. Lobo, J.V. Pinkerton, and M.L. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertil Steril 92 2009 1025 1038
24. J.H. Pickar, I.-T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 92 2009 1018 1024
25. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 2009 1039 1044
26. M.R. McClung, E. Siris, and S. Cummings Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Menopause 13 2006 377 386
27. M. McClung, E. Siris, and S. Cummings Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD J Bone Miner Res 20 2005 S97
28. M. Davidson, A. Moffett, and F. Welty Extraskeletal effects of lasofoxifene on postmenopausal women J Bone Miner Res 20 2005 S173
29. S.R. Cummings, K. Ensrud, and P.D. Delmas Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 2010 686 696
30. ® (lasofoxifene tartrate) 0.5 mg Tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. http://www.fdagov/ohrms/dockets/ac/08/briefing/ 2008-4381b1-02-Pfizer.pdf; 2008.
31. S.R. Goldstein, P. Neven, and S. Cummings Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes Menopause 18 2010 17 22
32. R.W. Downs Jr., A.M. Moffett, A. Ghosh, D.A. Cox, S.A. Dowsett, and K. Harper Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass Osteoporos Int 21 2009 1215 1226
33. M. Bolognese, J.H. Krege, and W.H. Utian Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass J Clin Endocrinol Metab 94 2009 2284 2289
34. S.R. Cummings, M. McClung, and J.Y. Reginster Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women J Bone Miner Res 2010 [Epub ahead of print]
35. G.A. Bachmann, and J.O. Komi Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause 17 2010 480 486
36. J. Komi, J. Heikkinen, E.M. Rutanen, K. Halonen, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol 18 2004 152 158 (Pubitemid 38328094)
37. J. Komi, K.S. Lankinen, and M. DeGregorio Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab 24 2006 314 318 (Pubitemid 43992675)
38. E.M. Rutanen, J. Heikkinen, K. Halonen, J. Komi, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial Menopause 10 2003 433 439
39. J. Komi, K.S. Lankinen, and P. Harkonen Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause 12 2005 202 209 (Pubitemid 40464289)
40. G. Hattersley, D.G. Paquin, and S. Ho RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms Abstract presented at the 89th Annual Meeting of the Endocrine Society June 2-5, 2007, Toronto, Ontario, Canada 2007
41. F. Labrie, C. Labrie, and A. Belanger EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium J Steroid Biochem Mol Biol 79 2001 213 225 (Pubitemid 34158798)
42. P.E. Goss, S. Qi, A.M. Cheung, H. Hu, M. Mendes, and K.P. Pritzker The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats J Steroid Biochem Mol Biol 92 2004 79 87 (Pubitemid 39486065)
43. O.B. Wallace, K.S. Lauwers, and J.A. Dodge A selective estrogen receptor modulator for the treatment of hot flushes J Med Chem 49 2006 843 846 (Pubitemid 43221631)